Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177062 | 0.90 | CNR2 (0.62) | CNR2MAPK1KDM4ECNR1LMNA | |
| SCHEMBL3177065 | 0.81 | CNR2 (0.94) | CNR2CNR1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL10253120 | 0.78 | CNR2 (1.00) | CNR2CNR1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2679182 | 0.77 | TP53 (0.58) | CNR2MAPK1CNR1LMNASMN1; SMN2 | |
| SCHEMBL10257398 | 0.77 | CNR2 (0.98) | CNR2CNR1SMN1; SMN2HSD11B1ALDH1A1 | |
| SCHEMBL4600115 | 0.75 | MAOB (0.44) | KDM4EALDH1A1 | |
| SCHEMBL10257403 | 0.75 | CNR2 (0.94) | CNR2CNR1SMN1; SMN2HSD11B1ALDH1A1 | |
| SCHEMBL15954401 | 0.74 | MAOB (0.47) | — | |
| SCHEMBL6966882 | 0.73 | NPC1 (0.57) | — | |
| SCHEMBL2678633 | 0.73 | TP53 (0.66) | CNR2MAPK1KDM4ECNR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885MAPK1 1130/4885KDM4E 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.